Active Filter(s):
Details:
The financing will be used for further strengthening the company’s pipeline and portfolio especially in Oncology area. Etana will produce Bevagen (bevacizumab biosimilar), a recombinant humanized anti-VEGF monoclonal antibody drug for cancer patients in Indonesia.
Lead Product(s): Bevacizumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Yunfeng Capital
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing March 20, 2023